Eton Pharmaceuticals (ETON) Cash & Equivalents (2017 - 2026)

Eton Pharmaceuticals has disclosed Cash & Equivalents across 10 years of filings, most recently posting $26.8 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 5.78% year-over-year to $26.8 million; the TTM figure through Jun 2026 stood at $26.8 million (up 5.78% YoY), while the FY2025 annual figure was $25.9 million, up 73.69% from the prior year.
• Cash & Equivalents came in at $26.8 million for Q2 2026 at Eton Pharmaceuticals, up from $25.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $37.1 million in Q3 2025 to a low of $13.4 million in Q3 2022.
• Average Cash & Equivalents over 5 years is $20.2 million, with a median of $17.7 million recorded in 2024.
• Year-over-year, Cash & Equivalents tumbled 41.09% in 2022 and jumped 83.21% in 2025.
• Over 5 years, Cash & Equivalents stood at $16.3 million in 2022, then surged by 31.17% to $21.4 million in 2023, then plunged by 30.17% to $14.9 million in 2024, then jumped by 73.69% to $25.9 million in 2025, then increased by 3.48% to $26.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $26.8 million in Q2 2026, $25.9 million in Q4 2025, and $37.1 million in Q3 2025.